Stay updated on FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Sign up to get notified when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.

Latest updates to the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page
- Check4 days agoChange DetectedNew navigation/help links were added to guide eligibility, contact, reading the study record, common questions, and how to join; the Intervention/Treatment header formatting was updated, and the revision label updated from v3.5.5 to v3.6.0.SummaryDifference0.5%

- Check12 days agoChange DetectedRevision: v3.5.5 replaces the previous v3.5.4 in the page footer, indicating a minor version update. This change appears to be a backend or CMS update and does not affect the study content or user-facing information.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page shows Revision: v3.5.4, replacing the previous v3.5.3, indicating an administrative update to the page. The change does not alter the study details or user-facing features.SummaryDifference0.1%

- Check47 days agoChange DetectedThe page's revision tag changed from v3.5.2 to v3.5.3, indicating a newer release version of the page.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check90 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0. No visible changes to the Study Details page content or layout.SummaryDifference0.1%

Stay in the know with updates to FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FirstLine Trabectedin, Ipilimumab, Nivolumab Clinical Trial page.